Ceapro Announces Results of 2023 Shareholders’ Meeting
June 07 2023 - 9:05AM
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF)
(“Ceapro” or the “Company”), a growth-stage biotechnology
company focused on the development and commercialization of active
ingredients for healthcare and cosmetic industries, announced today
that all proposed Directors were elected to serve for a one-year
term at its Annual General and Special Meeting of Shareholders held
on June 6, 2023 as per the following results:
Nominee |
Votes For |
Votes Against |
% of votes cast |
|
|
|
FOR |
AGAINST |
Geneviève Foster |
30,851,273 |
3,202,660 |
90.60% |
9.40% |
Gilles Gagnon |
24,113,376 |
10,025,707 |
70.63% |
29.37% |
Ronald W. Miller |
32,520,070 |
1,619,013 |
95.26% |
4.74% |
Ulrich Kosciessa |
28,909,104 |
5,229,979 |
84.68% |
15.32% |
William Li |
30,511,065 |
3,628,018 |
89.37% |
10.63% |
Mr. Glenn Rourke, who provided 15 years of
dedicated service as a director of the company, advised on June 5,
2023, that he was no longer standing for re-election. Therefore,
his name was removed from the slate.
All other matters at the Shareholders' meeting,
namely the appointment of auditors and the approval and
ratification of an amended and restated Stock Option Plan, as
proposed in the Company’s information circular dated April 19,
2023, were also approved by shareholders.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company
involved in the development of proprietary extraction technology
and the application of this technology to the production of
extracts and “active ingredients” from oats and other renewable
plant resources. Ceapro adds further value to its extracts by
supporting their use in cosmeceutical, nutraceutical, and
therapeutics products for humans and animals. The Company has a
broad range of expertise in natural product chemistry,
microbiology, biochemistry, immunology and process engineering.
These skills merge in the fields of active ingredients,
biopharmaceuticals and drug-delivery solutions.
For more information on Ceapro, please visit the
Company’s website at www.ceapro.com.
For more information contact:
Jenene ThomasJTC Team, LLCInvestor Relations and Corporate
Communications AdvisorT (US): +1 (833) 475-8247E: czo@jtcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBAPresident & CEOT:
780-421-4555
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Ceapro (TSXV:CZO)
Historical Stock Chart
From Apr 2024 to May 2024
Ceapro (TSXV:CZO)
Historical Stock Chart
From May 2023 to May 2024